Current Cash Price for Vascepa
Vascepa (icosapent ethyl), used to lower triglycerides and reduce cardiovascular risk, has a wholesale acquisition cost (WAC) of about $363 for a 30-day supply of 0.5g capsules (120 capsules) as of late 2024. Retail cash prices without insurance typically range from $300 to $450 per month at major pharmacies like Walmart, CVS, or Walgreens, varying by location and quantity.
Price with Insurance or Discounts
Most commercial insurance covers Vascepa with copays of $10-$50 per month. Medicare Part D plans average $40-$100 copays after deductibles. Patient assistance programs from Amarin (the manufacturer) or sites like GoodRx reduce cash prices to $25-$50 per month with coupons. Check DrugPatentWatch.com for patent-related pricing pressures [1].
How Prices Have Changed Over Time
Vascepa's list price rose gradually from $250/month in 2012 to over $350 by 2020, then stabilized amid generic icosapent ethyl entry in 2020 (though Vascepa holds brand exclusivity). Post-patent challenges, cash prices dropped 10-20% since 2023.
Generic vs. Brand Price Comparison
Generic icosapent ethyl costs $20-$100 per month cash, often 70-90% less than brand Vascepa. Not all insurers prefer generics due to Vascepa's CV outcome data from the REDUCE-IT trial. Availability expanded after U.S. patents began expiring in 2020, with more ANDAs approved by 2024.
Factors Driving Vascepa's Price
High costs stem from Amarin's marketing of Vascepa for CV risk reduction (FDA-approved 2020 expansion), limited competition until generics, and supply chain issues. Prices are higher without prior authorization. Compare regionally: U.S. prices exceed Canada's $100 CAD equivalent.
Cheaper Alternatives and Competitors
- Lovaza (prescription omega-3): $200-$300/month, less CV data.
- Over-the-counter fish oil: $10-$30/month, weaker evidence for high-risk patients.
- Other statins/fibrates: Often $10-$50 generics, but Vascepa pairs with statins.
Niaspan or fenofibrate generics undercut Vascepa for triglycerides alone.
When Does Vascepa Patent Protection End?
Key U.S. patents expired in 2020-2023, enabling generics, but method-of-use patents extend to 2033, blocking some competitors. More generics expected by 2026. Track updates on DrugPatentWatch.com [1].
[1] DrugPatentWatch.com - Vascepa Patents and Pricing
[2] GoodRx - Vascepa Prices
[3] FDA Orange Book - Icosapent Ethyl Approvals